----item----
version: 1
id: {78C3088F-2E06-46EE-928A-36E6634DD97D}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/03/16/Amicus to seek quicker market paths for Fabry drug
parent: {15CEDA49-DF2B-4F46-96A7-78145A6DFE0C}
name: Amicus to seek quicker market paths for Fabry drug
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 127e75cc-f320-49c8-857a-be00c7baabf6

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{C7FD764C-38F2-42BC-9F1A-A9864C90E18B}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 50

Amicus to seek quicker market paths for Fabry drug
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 50

Amicus to seek quicker market paths for Fabry drug
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1544

<p>Shares of Amicus Therapeutics soared 41% on 19 March after the company said it plans to seek an accelerated approval of its new drug application (NDA) in the US for its experimental Fabry disease drug migalastat.</p><p>The firm said it would submit the NDA in the second half of this year based on positive information from the FDA. </p><p>The company said it also intends to accelerate the timeline for its marketing authorization application in Europe for the investigational medicine.</p><p>Shares of the firm closed at $12.46 on 19 March, up $3.11, or 33.26%.</p><p>Amicus said based on positive feedback from the EMA, the firm plans to submit for full approval of migalastat as a monotherapy in the second quarter &ndash; moving the timing up from midyear.</p><p>Amicus previously reported positive Phase III migalastat data in its FACETS and ATTRACT trials, which demonstrated reductions in disease substrate, stability of kidney function, reduction in cardiac mass and a positive impact on patient-reported outcomes in patients with amenable mutations.</p><p><b>Related articles</b></p><p><a href="http://www.scripintelligence.com/home/Amicus-hit-hard-on-FDA-advice-for-more-migalastat-work-before-NDA-344159" target="_new">Amicus hit hard on FDA advice for more migalastat work before NDA</a></p><p><a href="http://www.scripintelligence.com/home/CEO-Crowley-Amicus-will-go-it-alone-on-migalastat-Phase-III-success-353476" target="_new">CEO Crowley: Amicus will go it alone on migalastat Phase III success</a></p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 219

<p>Shares of Amicus Therapeutics soared 41% on 19 March after the company said it plans to seek an accelerated approval of its new drug application (NDA) in the US for its experimental Fabry disease drug migalastat.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 50

Amicus to seek quicker market paths for Fabry drug
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150316T141117
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150316T141117
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150316T141117
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028179
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 50

Amicus to seek quicker market paths for Fabry drug
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357310
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042315Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

127e75cc-f320-49c8-857a-be00c7baabf6
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042315Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
